Skip to content

BMY vs JNJ: Dividend Comparison

BMY$60.78
Bristol Myers Squibb Co
Health Care
vs
JNJ$243.53
Johnson & Johnson
Health Care

Dividend data as of

Bristol Myers Squibb Co (BMY) and Johnson & Johnson (JNJ) are both in the Health Care sector, making them natural rivals for dividend investors. BMY offers a significantly higher 4.09% yield compared to JNJ's 2.16%, a gap of 1.93%. For dividend growth, BMY leads with a 5-year CAGR of 14.0% versus JNJ's 5.2%. JNJ holds the edge in dividend safety with a "Safe" rating. JNJ is a Dividend King with 63 years of consecutive increases.

Verdict

Best for Income
BMY
Higher yield at 4.09%
Best for Growth
BMY
5yr CAGR of 14.0%
Best for Safety
JNJ
Rated "Safe"
Metric
Price
$60.78
$243.53
Dividend Yield
4.09%
2.16%
Annual Dividend
$2.49
$5.14
5yr Div CAGR
14.0%
5.2%
3yr Div CAGR
20.4%
4.6%
Consecutive Years
0
63
Payout Ratio
71.97%
46.60%
P/E Ratio
—
—
Market Cap
—
—
Income on $10k
$409/yr
$216/yr

Yield Analysis

BMY
4.09%
JNJ
2.16%

BMY yields 1.93% more than JNJ. In dollar terms, BMY pays $2.49/share vs JNJ's $5.14/share annually.

Dividend Growth

BMY 5yr CAGR
14.0%
accelerating
JNJ 5yr CAGR
5.2%
decelerating

BMY: Dividend growth is accelerating — the 3-year CAGR of 20.4% exceeds the 5-year rate of 14.0% and the 10-year rate of 9.0%.

JNJ: Dividend growth is slowing — the 3-year CAGR of 4.6% trails the 5-year rate of 5.2% and the 10-year rate of 5.6%.

Dividend Safety

BMY
Moderate
Payout Ratio72%
JNJ
Safe
Payout Ratio47%

BMY: The payout ratio of 72% is moderate. The dividend is currently covered by earnings but leaves less room for growth. Earnings cover the dividend 1.4x.

JNJ: The payout ratio of 47% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 2.1x.

Estimated Annual Dividend Income

Based on current dividend yields. Actual income may vary.

Investment
BMY
JNJ
$10,000
$409/yr
$216/yr
$50,000
$2,046/yr
$1,078/yr
$100,000
$4,091/yr
$2,156/yr

What does $10,000 buy in BMY vs JNJ today?

At $60.77 per share, $10,000 buys about 164.5 shares of Bristol Myers Squibb Co (BMY). Each share pays $2.49 per year in dividends, so the position starts out generating roughly $410 per year — about $34 a month.

At $243.53 per share, $10,000 buys about 41.1 shares of Johnson & Johnson (JNJ). Each share pays $5.14 per year in dividends, so the position starts out generating roughly $211 per year — about $18 a month.

BMY is the larger income stream from day one: $199 per year more on the same $10,000 invested.

What could $10,000 of BMY or JNJ income look like in 10 years?

Bristol Myers Squibb Co (BMY) has raised its dividend about 14.0% a year over the past five years. If that pace held, the $409 per year that $10,000 generates today at the current 4.09% yield would reach $1,513 per year by 2036 — a 15.1% yield on the original cost.

Johnson & Johnson (JNJ) has raised its dividend about 5.2% a year over the past five years. If that pace held, the $216 per year that $10,000 generates today at the current 2.16% yield would reach $359 per year by 2036 — a 3.6% yield on the original cost.

On those trailing rates, BMY pays more in 2036: $1,513 versus $359 per year. The projection assumes each five-year growth rate persists and no dividends are reinvested — real payouts will differ.

When would JNJ's dividend growth overtake BMY's higher yield?

It doesn't, on the trailing numbers. Bristol Myers Squibb Co (BMY) yields more today (4.09% vs 2.16%) and has also grown its dividend at least as fast (14.0% vs 5.2% a year over five years). Unless JNJ accelerates its raises or BMY stumbles, JNJ never closes the income gap — BMY wins on both current income and growth.

Can BMY and JNJ afford their dividends?

Bristol Myers Squibb Co (BMY) earns $3.46 per share against $2.49 paid out in dividends — 1.4x coverage (a 72% payout ratio).

Johnson & Johnson (JNJ) earns $11.03 per share against $5.14 paid out in dividends — 2.1x coverage (a 47% payout ratio).

JNJ's wider coverage leaves more cushion if earnings dip. As a rule of thumb, coverage below about 1.5x (a payout ratio above ~65%) is where a dividend starts to look stretched — worth watching for BMY if earnings weaken.

Which fits an early-retirement income portfolio better, BMY or JNJ?

For income you need right now, Bristol Myers Squibb Co (BMY) leads: $100,000 invested today pays about $341 a month at the current 4.09% yield, versus $180 a month from Johnson & Johnson (JNJ) at 2.16%.

BMY also leads on dividend growth (14.0% vs 5.2% a year over five years), so the trailing numbers favor it on both fronts.

On consistency: JNJ has raised its dividend 63 consecutive years.

Many income investors simply hold both — the mix pairs current yield with growth and spreads single-name risk. Whichever way you lean, dividends are never guaranteed; recheck the payout each quarter rather than setting and forgetting.

$10,000 with DRIP: projected annual income

If each holding keeps raising its dividend at its real 5-year rate and every payment is reinvested, a $10,000 position pays $2,259/yr in BMY vs $445/yr in JNJ by year 10.

Assumes dividends are reinvested at the current yield and grow at each holding's trailing 5-year dividend CAGR. A projection, not a prediction — no price appreciation modeled.

Track BMY and JNJ in your portfolio

See your real income from both — forward projections, yield on cost, and dividend safety signals. Sync your brokerage free for 30 days, or track holdings manually on the free plan.

Choosing a tracker? See the best dividend trackers compared.

Frequently Asked Questions

This tool is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. Consult a licensed professional before making investment decisions.

Past performance does not guarantee future results. All projections are hypothetical estimates based on user-provided inputs and may differ materially from actual outcomes.

By using this tool you agree to our Terms of Service and Privacy Policy.